CureVac
Patrick Baumhof has extensive work experience in the biotech industry. Patrick began their career at QIAGEN as a Scientist from June 2005 to June 2007. Patrick then joined CureVac and held various roles, including Senior Scientist from July 2007 to April 2014. From April 2014 to December 2016, they served as the Head of Product Design & Formulations. Patrick later became the Vice President of Formulation & Delivery from January 2017 onwards. In July 2021, they were promoted to Senior Vice President in the same department. Recently, as of January 2022, they took on the role of Senior Vice President of Technology at CureVac.
Patrick Baumhof attended the Karlsruhe Institute of Technology (KIT) from 1994 to 2000, where they earned their degree in chemie in the year 2000.
This person is not in any teams
This person is not in any offices
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.